Javascript must be enabled to continue!
Efficacy and safety of vortioxetine in cardiological patients
View through CrossRef
IntroductionThe most important conditions for the using of antidepressants in cardiological practice are good tolerability, minimal interaction with other drugs, and the absence of a toxic effect. All of the above qualities among antidepressants have a multimodal antidepressant – vortioxetine.ObjectivesEvaluation of the efficacy and safety of vortioxetine in the treatment of concomitant depressive disorders in cardiological patients.Methods37 patients aged 45-66 years who were admitted for inpatient treatment at the Regional Clinical Cardiology Dispensary with a diagnosis of “coronary heart disease, Angina pectoris II-III FC” were examined. Upon the hospitalization, they were consulted by a psychiatrist. During the consultation, the patients were diagnosed with a Major depressive disorder, single episode, moderate (F 32.1 according to ICD – 10). Therapy of depressive disorder was carried out in average therapeutic doses with vortioxetine for 8 weeks. To evaluate the efficacy, scales and questionnaires were used: HADS, PDQ–20, CGI–C, SF–36. Statistical processing of the material was carried out using a package of applied statistical programs: Excel, Word (version 2108).ResultsAnalysis of the results of assessing the severity of depressive and anxiety manifestations on the HADS scale and the level of cognitive functioning using the PDQ questionnaire allowed us to state that at the end of 8 weeks of therapy with vortioxetine, 89% of patients showed significant clinical improvement. The positive dynamics of patients is confirmed by data on the CGI–C scale. The answers to the SF–36 questionnaire indicate an improvement in the life quality indicators. Statistically significant changes were observed in the parameters “Physical condition”, “Mental health” and “Vital activity”.The tolerability of vortioxetine in all patients was good, side effects in 13.5% of the subjects in the form of dizziness, nausea and daytime drowsiness were reduced within 1 week.There were no significant changes in the biochemical parameters of blood, coagulogram, electrolyte composition. When assessing the indicators of blood pressure, heart rate, there was a significant improvement in indicators by the end of the research. In 8 weeks, the frequency of angina attacks and arrhythmias significantly was decreased.ConclusionsWhen prescribing vortioxetine to patients with cardiological pathology for 8 weeks, there was distinct positive dynamics both in terms of indicators of the cardiovascular system, and in the emotional sphere, cognitive and social functioning.Disclosure of InterestNone Declared
Title: Efficacy and safety of vortioxetine in cardiological patients
Description:
IntroductionThe most important conditions for the using of antidepressants in cardiological practice are good tolerability, minimal interaction with other drugs, and the absence of a toxic effect.
All of the above qualities among antidepressants have a multimodal antidepressant – vortioxetine.
ObjectivesEvaluation of the efficacy and safety of vortioxetine in the treatment of concomitant depressive disorders in cardiological patients.
Methods37 patients aged 45-66 years who were admitted for inpatient treatment at the Regional Clinical Cardiology Dispensary with a diagnosis of “coronary heart disease, Angina pectoris II-III FC” were examined.
Upon the hospitalization, they were consulted by a psychiatrist.
During the consultation, the patients were diagnosed with a Major depressive disorder, single episode, moderate (F 32.
1 according to ICD – 10).
Therapy of depressive disorder was carried out in average therapeutic doses with vortioxetine for 8 weeks.
To evaluate the efficacy, scales and questionnaires were used: HADS, PDQ–20, CGI–C, SF–36.
Statistical processing of the material was carried out using a package of applied statistical programs: Excel, Word (version 2108).
ResultsAnalysis of the results of assessing the severity of depressive and anxiety manifestations on the HADS scale and the level of cognitive functioning using the PDQ questionnaire allowed us to state that at the end of 8 weeks of therapy with vortioxetine, 89% of patients showed significant clinical improvement.
The positive dynamics of patients is confirmed by data on the CGI–C scale.
The answers to the SF–36 questionnaire indicate an improvement in the life quality indicators.
Statistically significant changes were observed in the parameters “Physical condition”, “Mental health” and “Vital activity”.
The tolerability of vortioxetine in all patients was good, side effects in 13.
5% of the subjects in the form of dizziness, nausea and daytime drowsiness were reduced within 1 week.
There were no significant changes in the biochemical parameters of blood, coagulogram, electrolyte composition.
When assessing the indicators of blood pressure, heart rate, there was a significant improvement in indicators by the end of the research.
In 8 weeks, the frequency of angina attacks and arrhythmias significantly was decreased.
ConclusionsWhen prescribing vortioxetine to patients with cardiological pathology for 8 weeks, there was distinct positive dynamics both in terms of indicators of the cardiovascular system, and in the emotional sphere, cognitive and social functioning.
Disclosure of InterestNone Declared.
Related Results
Post-marketing safety surveillance of vortioxetine: a real-world study using the FAERS database
Post-marketing safety surveillance of vortioxetine: a real-world study using the FAERS database
Aims: The FDA Adverse Event Reporting System (FAERS) database was used
to study vortioxetine-associated adverse events (ADEs) in a real-world
setting to provide recommendations for...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION: A MULTICENTER STUDY
PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION: A MULTICENTER STUDY
Objective: To find out how common cognitive impairment is in people with major depressive disorder (MDD) and assess how well vortioxetine works for treating both cognitive dysfunct...
Hepatic Inflammation and Apoptosis in Socially Isolated Rats: Effects of Vortioxetine Treatment
Hepatic Inflammation and Apoptosis in Socially Isolated Rats: Effects of Vortioxetine Treatment
Background: Depression and chronic psychosocial stress can induce systemic inflammation and oxidative stress that may extend beyond the central nervous system to peripheral organs ...
The Burden of Road Traffic Injuries: A Global Perspective
The Burden of Road Traffic Injuries: A Global Perspective
Introduction Road Traffic Injury (RTI) pose a significant health challenge. It represents the eighth leading cause of death globally, prompting the UN to designate 2011-2020 as...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
CARDIOLOGICAL HYPERTENSIVE EMERGENCIES: REAL WORD DATA COMPARED TO GUIDELINES INDICATIONS
CARDIOLOGICAL HYPERTENSIVE EMERGENCIES: REAL WORD DATA COMPARED TO GUIDELINES INDICATIONS
Objective:
The 2018 ESH guidelines have revised the therapeutic goals of cardiological Hypertensive Emergencies (HE). Cardiac acute organ damage during HE includes acut...
New insights into chronic pain management based on biopsychosocial model
New insights into chronic pain management based on biopsychosocial model
The biopsychosocial model of pain dominates the scientific community’s understanding of chronic pain. Chronic pain is considered a different form of depression. In this study, pain...

